I agree with Easy Street. I think the next announcement will be about the FDA's response re: the number of Phase 3 trials required. We're expecting that the FDA - once they see the Phase 2 data - will only ask IXC to conduct one trial (in line with the EMA's recommendation). If this happens, we should see a rise in the share price. As FiftyOneCapital stated in their podcast, the stock will likely re-rate once the Phase 3 trials are under way, so we just need to be patient (IMO, DYOR)
Add to My Watchlist
What is My Watchlist?
